Launch week offerEnds in00h00m00s

annual Promonthly Pro

Aaron Mitchell

Assistant Attending

Memorial Sloan Kettering Cancer Center

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (10)

Stacie B. Dusetzina

Professor

Vanderbilt University School of Medicine

UNITED STATES

View details

Caroline Carlin

Research Investigator

University of Minnesota

UNITED STATES

View details

Jeah Jung

Professor

George Mason University

UNITED STATES

View details

Benjamin Rome

Assistant Professor of Medicine

Brigham and Women's Hospital

UNITED STATES

View details

Gabriela Spilberg

Assistant professor- Director of theranostics and Clinical trials

Yale University

UNITED STATES

View details

James Yu

Professor

Dartmouth-Hitchcock Medical Center

UNITED STATES

View details

Michaela Dinan

Professor

Yale University

UNITED STATES

View details

Nina Galanter

Research Scholar

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Preston Sprenkle

Associate Professor

Yale University

UNITED STATES

View details

Reshma Ramachandran

Yale University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aaron Mitchell

Research Interests

Make your next move.

Explore related searches

Articles (20)

Use of low-value cancer care in practices acquired by private equity firms

Industry promotion of oncology drugs with accelerated approval that failed confirmatory trials

Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer

Pricing Trends and Overlapping Indications of Checkpoint Inhibitors for Cancer Treatment

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare.

Changes in Cost of Guideline-Concordant Cancer Treatment: Observations and Implications

Timeliness of Prostate Cancer Treatment in Medicare Advantage and Traditional Medicare: More Similarities than Differences?

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses

Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer.

When Priority Review No Longer Prioritizes

Biosimilar Competition in Oncology-Beyond Insurer Pressure.

Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.

How often do oncologists receive industry payments from competing companies?

Postmarket Safety Actions for Novel Oncology Drugs Granted FDA's Accelerated Approval.

Oncology Drug Revenue and Price Negotiation.

What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review

Provider billing margin and cancer treatment selection: population based cohort study

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

More Industry Payments and More Patient Complaints-What Explains This Link?

Collaborators (10)

Stacie B. Dusetzina

Caroline Carlin

Jeah Jung

Benjamin Rome

Gabriela Spilberg

James Yu

Michaela Dinan

Nina Galanter

Preston Sprenkle

Reshma Ramachandran

Make your next move.